Speakers & Panels – 2018 Questrom Health & Life Sciences Conference

Friday, November 2, 2018 at the Boston University Questrom School of Business

Opening Keynote Speaker: Healthcare Transformation and the Imperative to Integrate

Michael Wagner, MD Chief Physician Executive, Wellforce

Dr. Michael Wagner is the Chief Physician Executive of Wellforce, a growing health system in Eastern Massachusetts that has been recognized for its high quality, lower cost value position and its commitment to community care. Prior to this role, Dr. Wagner served for five years as President and CEO of Tufts Medical Center, the academic medical center of Wellforce. He began his tenure at Tufts MC straight out of his residency in 1990 as a member of the academic faculty practice of General Medicine. He then held clinical and administrative roles at hospitals affiliated with the University of Rochester in Rochester, NY. Wagner also served as Chief Medical Officer of Fidelis Care New York and Regional Medical Director of Cove HealthCare in White Plains, NY. In 1999, he returned to Tufts MC as Chief of General Medicine, later adding the title of Vice President of Ambulatory Services. From 2003 to 2008, Dr. Wagner served as Chief Executive Officer of the Inpatient Services division of EmCare, a national hospitalist physician practice management company in Dallas.  He serves on various boards and is a graduate of Connecticut College and Georgetown University School of Medicine. He completed his residency in Internal Medicine at Dartmouth Hitchcock Medical Center in Hanover, NH.

Platform Based Technologies: Responding to Increasing R&D Costs

Ballooning R&D costs within the pharmaceutical space have led firms to pursue the development of platform-based treatments. This strategy can diversify risk across multiple development candidates by limiting the costs associated with researching multiple unrelated drug candidates. Concurrently, firms hope that the approval of one method of treatment using a platform technology will ease regulatory requirements for its use toward other diseases, producing cheaper and faster-to-market drugs. This panel will bring stakeholders from the biotechnology industry, investors, insurance companies, and regulatory professionals together to speak about the challenges to this strategy and how they can work to achieve positive outcomes for both patients and shareholders.

MODERATOR: Mark Philip, Ph.D, MBA CEO, Onkimmune Ltd; President, Mark Philip Consulting LLC; Lecturer, Boston University

Mark Philip has over 30 years of experience in the Biopharma, Medical Device and
Diagnostic industries, operating in Europe, the USA and Asia. As CEO, president or board
member of multiple start-ups, medium-sized and large businesses, Mark has orchestrated
multiple turnarounds, built product pipelines, launched new products, sold companies and
created significant shareholder value.
Mark is currently a consultant to the industry advising on acquisitions, product development,
commercial strategies and fundraising for a variety of small and large, private and public
companies. Mark is also on the faculty at Boston University’s MBA Program and teaches
advanced strategy in the pharmaceutical, medical device and diagnostics industries.

Ivan Hyep, BS Finance, MBA Director of Finance, Third Rock Ventures

Ivan Hyep is a Director of Finance at Third Rock Ventures where he focuses on portfolio management, investor relations and launching new biotech companies. In addition, he currently is spending time with Rheos Medicines, a biotech company developing medicines based upon the emerging field of immunometabolism, as well as early-stage portfolio companies to focus on value creation models, strategic financing and indication-based planning.

Prior to joining Third Rock, Ivan was a finance manager at Bain Capital. There, he was responsible for managing a coinvest private equity portfolio and leading the development of internal investment portals. Ivan holds an MBA with high honors in finance and entrepreneurship from the Boston University Questrom School of Business and a B.S. in finance from Bentley University. 

Bruce A. Beutel, Ph.D Entrepreneur in Residence, LS Polaris Innovation Fund

Dr. Beutel has over 25 years of leadership experience in drug discovery and business development.  Most recently as Chief Business Officer at SQZ Biotechnologies, and as Executive Director in Business Development & Licensing at Merck, he led deal teams to achieve several significant pharma-biotech transactions focused on new therapies enabled by platform technology.  He previously led Drug Discovery Research groups in a variety of disease and technology areas in various management roles at Merck and Abbott, as well as Chief Scientific Officer at Znomics.  Dr. Beutel has over 30 peer reviewed publications and 7 issued patents. He received his B.A. in Biology from the University of Chicago and his Ph.D. in Molecular Biology from the University of Wisconsin-Madison.

Denis J. Schrier, PhD Executive Director, Nonclinical Development, Inozyme Pharma; President, CLAD Preclinical Development, LLC

Denis Schrier has over 35 years of experience in the pharmaceutical and biotechnology industries.  He received a PhD from the Medical College of Wisconsin and a fellowship in Pathology at the University of Michigan.  Denis has extensive experience as a pharmacologist and in drug safety. He began his career at Pfizer where he contributed to the development of  compounds including Lyrica® and Lipitor®.  Denis later  joined Stryker Regenerative Medicine where he led the preclinical effort to develop BMP-7 used for  orthopedic disorders. BMP-7 was approved in the European Union for spinal fusion.   Denis subsequently joined Alexion where he led the Toxicology Group.  He worked on complement inhibitors and drugs for genetic diseases such as hypophosphatasia. Stensiq® and Kanuma® were registered during his tenure.  He currently works as an independent  consultant and is an Executive Director with Inozyme Pharma, a rare disease company.   He has well over 100 publications and presentations.

Jason P. Hafler, PhD, BS Senior Director of Investments, Sanofi-Genzyme BioVentures

Jason joined Sanofi Ventures in 2014 with a background in early stage biotech investing and transactions. Prior to Sanofi, Jason was the Director of Corporate Development at RaNA Therapeutics, a company co-founded by his previous firm Atlas Venture. At Atlas, Jason was an Associate in the Life Sciences group and a Board Observer for several portfolio companies. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the University of Cambridge while performing his doctoral research.

Jason currently serves on the Board of Directors for NeuroVia and Expansion Therapeutics; he is a board observer for Navitor Pharmaceuticals. Additionally, he is on the Board of Directors for one additional Sanofi Ventures-backed seed stage company. He is also on the Board of Trustees at the Buckingham Browne and Nichols school, the Board of Directors of The Magdalene College Foundation, and the Board of Directors of the Beacon Hill Nursery School.

Business Development: Partnerships & Collaboration

As more and more firms in the healthcare space consolidate, organizations are beginning to see the value in partnership for the sake of business development. Though many small biotechnology firms license out to big pharmaceutical companies in the interests of commercialization, the trend is showing that partnerships are spanning industry borders. This includes insurance companies leveraging the booming technology industry, and drug companies seeking a way to cushion the fall from their approaching patent cliffs. This panel will seek to explore how stakeholders pursue these partnerships, from the execution of due diligence to the negotiation of profit-sharing, and whether this consolidation is driving the innovation society needs.

MODERATOR: David Barone, BSc, MSc Biomedical Engineering, MBA Principal, Boston MedTech Advisors

David Barone’s background consists of 25 year experience in the healthcare and medical industry in the US, including general, technical and operations management, strategic planning, marketing and business development.  David Barone held senior management positions in a number of medical device companies, overseeing product development, marketing, pilot manufacturing, clinical evaluations, regulatory affairs and intellectual properties.  In addition, David Barone is an accomplished entrepreneur, founding, financing and growing several healthcare service organizations.  While leading these companies, David Barone entered into clinical and business affiliations with many top-tier medical centers in the US, negotiated and successfully contracted with many of the national and regional health plans, and evolved high quality and efficient clinical delivery systems.  David Barone has consulted and assisted US and off-shore medical technology organizations, ranging from start-ups to Fortune 500 companies, in diverse areas including market development, opportunity analysis, regulatory and reimbursement strategies, business development, financing and more. B.Sc., Electrical Engineering, Technion, Israel Institute of Technology, M.Sc., Bio-Medical Engineering and Master, Business Administration, both from Rensselaer Polytechnic Institute, NY.

Devin Nadar, BA Partnerships Manager, Innovation & Digital Health Accelerator- Boston Children’s Hospital

Devin Nadar is the Partnerships Manager for the Innovation and Digital Health Accelerator at Boston Children’s Hospital. In her role, she focuses on cultivating strategic partnerships with outside organizations that align with the goals and mission of the hospital. By sourcing partnerships and relationships with companies that range from disruptive start-ups to established industry leaders, Boston Children’s Hospital aims to rapidly but thoughtfully build products, platforms, and ventures that address the hospital’s clinical pain points but will also scale beyond the walls of the hospital. She also leads product and business development for select companies and projects in the Accelerator.

Kareem Reda, MBA, BS Head of Business Development and Corporate Strategy, Evelo Biosciences, Inc.

Kareem Reda is the Head of Business Development and Corporate Strategy at Evelo, a monoclonal microbial company developing novel medicines for inflammatory diseases and cancer. Prior to joining Evelo, Mr. Reda was a director of business development at Celgene where he led dozens of deals including licenses and collaborations, equity investments, and mergers and acquisitions. Mr. Reda helped develop and lead Celgene’s immuno-oncology strategy in business development. He spearheaded Celgene investments in the space including CAR-T, checkpoint antibodies and innate immune approaches. Prior to this, he worked in the formulation group at Vertex where he focused on Kalydeco®, approved for the treatment of cystic fibrosis. Kareem received his B.S. in Chemical Engineering from Brown University and his MBA from Harvard Business School.

Jonathan Rea, MBA, BBA Director of Business Development, Boston Scientific Endoscopy

Jonathan has had a successful 18-year medical device career in areas ranging from finance, sales, marketing, and business development at Boston Scientific.  Prior to Boston Scientific, he began his career in finance at Raytheon.

Robert Flynn, MBA, MA, BA Principal, Fuld + Company

Robert Flynn is an accomplished Strategy and Marketing executive in consulting, corporate and government. At Fuld + Company, Bob is Principal + CMO, providing strategic counsel to corporate leaders.

Bob served as Interim CMO and Special Assistant to the President at Travelers. He founded the Connecticut Governer’s Insurance Cluster, a CEO-level economic development collaboration. He underwrote group health policies at Aetna and at Deloitte Consulting, led risk engagements with Fortune 1000 firms. At the Central Intelligence Agency, he served as Cheif of Base in the Middle East and earned CIA and UN commendations for his leadership on Persian Gulf issues.

He is a published author, recently cited in Fortune.

Bob earned his MBA from the University of Connecticut, graduating with Highest Honors distinction, Beta Gamma Sigma. He earned a MA in International Affairs from the Fletcher School of Law and Diplomacy at Tufts University and holds a BA from Trinity College.

Changing Approaches to Mental Healthcare

There is increasing awareness and conversation around the insufficient care for mental health disorders in the US. While the US healthcare system is looking for new ways to provide mental healthcare and seeking to close the gap in available resources and services, there is an ongoing debate about how to provide these services and pay for them. Our panelists will discuss the ways in which behavioral health is being integrated into our healthcare delivery system, the progress made in improving mental health services, and the remaining gaps and barriers that require the focus of healthcare professionals moving forward.

MODERATOR: Andrea Sodano, Ph.D Executive-in-Residence for Health & Life Science Programs, Boston University

Andrea Sodano, Ph.D. is an Executive in Residence at the Questrom School of Business.  She has held executive positions at IBM, Symmetrix, the Hay Group and Wal-Mart. Her primary focus has been business transformation, consulting, and organization change. She also was a senior consultant and adjunct faculty at Dartmouth Medical School. She holds a Ph.D. from the University of Massachusetts in Clinical and Organization Psychology. She was a predoctoral intern at Yale Medical School and held a postdoctoral fellowship at Harvard Medical School. She is a member of the Boston Club and holds Board positions with the Massachusetts School of Professional Psychology and Eastman Community Association. She currently is the Faculty Director of the Health Sector Management Internship Program and the Dean’s Health and Life Sciences Fellows Program.

Nicholas A. Covino, PsyD President, William James College

Since becoming President in 2002, Dr. Nicholas Covino has led the school in new directions, while maintaining its underlying mission and values, which focus on providing mental health care to the underserved and meeting the needs of a changing society.  Dr. Covino has grown the school from a single-degree institution to a college that now grants 12 separate master’s and doctoral degrees and a bachelor’s completion program.  Prior to his current position, Dr. Covino was the Director of Psychology and Director of Training at the Beth Israel Deaconess Medical Center in Boston and was on the faculty of Harvard Medical School.  He received his PsyD degree from the University of Denver.

Charlie Sposato, MBA, MS Assistant Vice President, Growth and New Ventures for Beacon Health Option

As Assistant Vice President of Growth and New Ventures, Charlie Sposato is responsible for leading the development of Beacon’s corporate strategy and driving a portfolio of initiatives to grow the company’s footprint in new and existing markets.

Before joining Beacon, Charlie was a Manager at Alvarez and Marsal, where he specialized in assisting state Medicaid programs with budgeting and fiscal management, particularly in the area of long-term services and supports.

Luis Caraballo, PsyD Senior Director of Behavioral Health, Codman Square Health Center

Luis Caraballo holds a doctoral degree in Clinical Psychology from Ponce Health Sciences University in Puerto Rico and completed his Post-Doctoral Fellowship in Primary Care Psychology from UMass Med School, Worcester MA.

In 2006 he was appointed as the Director of Outpatient and Substance Use Services from the Department of Mental Health in Puerto Rico.  He used this position to promote BH Integration and was able to open the first 3 integrated care clinics on the PR-DMH system.  He then transitioned to academia with a faculty position in the Psychiatry Residency of the University of Puerto Rico.  In this role, he was able to develop integrated care services within the Anesthesiology, Gastroenterology and Neurosurgery clinics.

Since July 2016, he has been the Senior Director of Behavioral Health at Codman Square Health Center in Dorchester, MA where he has been leading the efforts of transforming the Behavioral Health Department into fully integrated primary care settings.

The Art of Aging: New Ideas for Older People

With the Baby Boomers reaching retirement age, there is increasing concern around how our society will care for the growing elderly population, and with it the increasing incidence of chronic disease. The question on the horizon is how services and technologies, ranging from continuing care to medical devices, can be more seamlessly integrated into the process of aging to improve quality of life from retirement through the end-of-life. Our panelists will discuss how their organizations are working to transform the experience of aging, while perhaps also capitalizing on the business opportunity to provide solutions for a generation seeking to age comfortably in their homes and communities.

MODERATOR: Ned Rimer, MBA, M.Ed Faculty Director, Executive-in-Residence, Senior Lecturer for Health Sector Management Program, Boston University

Ned is a social entrepreneur and educator. He is the Faculty Director of the Health Sector Management Program at Questrom, serving as a Senior Lecturer and Executive-in-Residence. Ned was previously the Founder and Executive Director of Chronic Care Community Corps, a healthcare reform initiative. He was also CEO and co-founder of a start-up for innovative palliative care, as well as co-founder and Managing Director for Citizen Schools, where he continues to serve on the board.

Ned has international work experience, having been trained by the American Red Cross as an international delegate for global natural disasters.

He serves on the Health Story Collaborative board, is an Innovation Fellow at the MGH Center for Innovations in Care Delivery, and is an alumnus of LeadBoston.

Ned earned a B.A. in Political Science from the University of Vermont, an MBA from Boston University, and a M.Ed. from Harvard University.

Mary Moscato, MBA, MPH President, Health Care Services and Rehabilitation Center, Hebrew SeniorLife

Mary Moscato is President of Hebrew SeniorLife Health Care Services and Hebrew Rehabilitation Center in Boston where she oversees a comprehensive and integrated network of senior care and post-acute services. She is a seasoned health care executive with 25+ years in C-level, progressive experience in post-acute care delivery systems and management of multi-site clinical operations.  She is recognized nationally for her advocacy role regarding the impact on federal policy for specialty hospitals, community-based programs and aging service programs as well as her leadership in implementing alternative payment models in the post-acute sector.  Prior to joining Hebrew SeniorLife, Mary held the positions of Chief Executive Officer at Care Alternatives, a multi-site provider of home and community-based services and Senior Vice President of the Northeast Region for HealthSouth Rehabilitation Hospitals.

Mary holds an MBA and MPH from Boston University, and a BS from Northeastern University.

She is a Fellow in the American College of Healthcare Executives, a member on the American Hospital Association Council for Long Term Care and Rehabilitation Hospitals, and serves as a guest lecturer at Boston University and Rutgers University.

R. Ripley Martin, MBA, BA General Manager, Home Monitoring and Population Health Management, Philips

Mr. Martin is responsible for leading Philips’ Aging & Caregiving product suite of personal emergency response services and solutions, medication management and solutions to support seniors in home and senior living facilities.

Prior to his current role, he led Philips’ strategy and business development efforts across the professional healthcare domain, including Philips’ healthcare informatics and services, patient monitoring, and imaging systems businesses and was responsible for all upstream marketing across Philips’ informatics businesses.  During his 5.2 years with Philips, he has been instrumental to Philips’ migration toward a common data environment and shift from products to software and services.

Prior to Philips, Ripley spent six years with the Boston Consulting Group (BCG) where he was a Principal in the firm’s Healthcare, Industrial Goods and Strategy practices. His work at BCG centered on value creation from disruptive technologies and business models, notably in the medical device and automotive sectors.

He earned his MBA with high distinction from the Ross School of Business at the University of Michigan, and his BA in Economics from Colby College.  

He lives in the greater Boston area with his wife and two children.

Alden Doerner Rinaldi, MD Medical Director, CareGroup Parmenter/Mount Auburn Hospital

Dr. Alden Doerner Rinaldi is a neurologist, palliative care physician, and Harvard Medical School Instructor of Clinical Medicine. He currently serves as Hospice Medical Director for Caregroup Parmenter Homecare & Hospice as well as Director for Community and Inpatient Palliative Care at Mount Auburn Hospital. In these leadership roles, he focuses on innovating services across the continuum of care for those living with serious illness and aging in place. He completed his medical degree at the State University of New York—Downstate and his neurology residency at Columbia-Presbyterian Hospital, both in New York City, before moving to Boston to pursue additional fellowship training in palliative care at Massachusetts General Hospital, Dana-Farber Cancer Center, and Brigham & Women’s Hospital.

Precision Medicine: Personalizing Treatments

With access to genetic information becoming more affordable, stakeholders are looking to customize their treatment offerings in an effort to achieve greater positive health outcomes for their patients, while distinguishing themselves from their competitors. While utilizing biomarkers comes with the promise of connecting patients to innovative treatments and the possibility of one-off treatments for conditions previously considered terminal, this cutting-edge technology remains far too expensive for scalable application. This panel will consider if and when these revolutionary therapies will be delivered, and subsequently how drug developers, patients, and payers will reconcile these factors with their associated costs.

MODERATOR: Diane Wuest, PhD, BS Director, Global Digital Business Development & Licensing, Sanofi

Dr. Diane Wuest is the Director of Global Digital Business Development & Licensing where she is responsible for digital business development efforts that align with Sanofi’s digital strategy across business units and functions, which range from discovering and developing therapies more efficiently to technology enabled drugs plus solutions (technology, services, and solutions) that improve patients’ outcomes and experiences at reduced costs. Prior to Sanofi, Diane was the Director of Precision Medicine Initiatives at GNS Healthcare, an AI and machine learning startup, where she developed strategic relationships with pharma, foundations, providers, and technology companies to elucidate disease mechanisms, advance drug discovery and development, and improve patient care. Prior to GNS, Diane worked for Genentech in R&D in support of an oncology clinical campaign, and her graduate work focused on building a model system for brain disease. Diane received her PhD and BS in Chemical & Biomolecular Engineering from the University of Delaware and Cornell University, respectively.

Brad Smith, PhD, MS, BA Vice President, Translational Medicine-IQVIA

Dr. Smith is currently the Vice President of Translational Medicine in the Strategic Drug Development Group within IQVIA.  In this position, Dr. Smith leads precision medicine and companion diagnostic strategy and planning client interactions including clinical, laboratory, corporate and commercial projects.  He brings more than 20 years of experience in biological research in academia and biotechnology including 9 years in planning and design of clinical studies in drug development.  Prior to IQVIA, Dr. Smith spent 10 years at Cell Signaling Technology, responsible for technical and corporate development of biomarker and diagnostic businesses.  He is the author of multiple basic research, translational medicine and clinical publications and patents and has a Ph.D. from Stanford University and held post-doctoral fellowships at Stanford University and UCSF.

Gaurav Singal, MD Vice President, Data Strategy & Product Development, Foundation Medicine

Gaurav Singal, M.D. is vice president of Data Strategy and Product Development at Foundation Medicine, where he is responsible for developing enterprise-wise data strategy and overseeing the development of a portfolio of data products including clinical care and analytic software tools, molecular trial recruitment services, and real world data solutions. He is also a practicing physician at Brigham and Women’s Hospital and a faculty member at Harvard Medical School where he directs a course on health technology and innovation. Prior to his role at Foundation Medicine, he received his B.S., summa cum laude, in computer science with a focus on AI and machine learning from Columbia University, earned an M.D. with honors from the Harvard-MIT division of Health Sciences and Technology, and completed residency training in Internal Medicine at Massachusetts General Hospital.

Matt Lasmanis, MBA, Fellow, BA Vice President of Technology, GSK USA

Matt Lasmanis is a senior executive, business strategist, and award-winning technology leader. He is currently Vice President of Technology at GSK USA, GlaxoSmithKline’s $10B US pharmaceuticals business. Matt’s previous roles include Global VP for Digital & Multichannel Engagement and Global IT Director for GSK Biotechnology R&D. Previous to GSK, Matt was head of digital platforms for HarperCollins Publishers, and head of Analytics Architecture for a leading media firm. Matt speaks and writes externally on the topics of digital transformation, social change, and strategic leadership.

Preston Estep, PhD, BS Director, Harvard Personal Genome Project; Co-founder and Chief Scientific Officer, Veritas Genetics; Co-founder and Chief Scientific Officer, Samplify Bio; Founding Advisor, Nebula Genomics

Dr. Preston Estep, III received his Ph.D. in Genetics from Harvard University for his graduate work in the lab of genomics pioneer Professor George Church. Dr. Estep is a Director of the Personal Genome Project at Harvard Medical School and manages genome sequencing at the PGP. He is a co-founder and Chief Scientific Officer of Veritas Genetics, a global genetic testing and genome sequencing company. Dr. Estep advises many startups in genomics and biomedical data management and analysis. He was an adviser to Curoverse, Inc., a pioneering creator of open-source software, genome processing pipelines, and big data machine learning tools, until its acquisition by Veritas Genetics in 2017. He is a founding advisor to Nebula Genomics, a blockchain genomics company launched in 2017. Dr. Estep is the author of the Mindspan Diet (Ballantine-Random House, 2016), a scientific analysis of the main determinants of physical and mental longevity.

An Elusive Goal: Driving Adherence & Engagement

Patient non-adherence to medications and other therapies is associated with poor health outcomes, disease progression, and estimated billions in avoidable costs. But with the advent of connected and advanced technologies, companies and innovators across the healthcare ecosystem are developing creative ways to engage patients and improve treatment adherence, whether by integrating technology with a pharmaceutical to create a digital pill or personalizing patient education. Approaching this intractable challenge from varied perspectives, our panelists will discuss new approaches to incentivize, motivate, and maximize patient adherence and engagement through their business’ core competencies.

MODERATOR: Gemmae M. Fix, PhD Research Assistant Professor, Boston University, School of Public Health, Department of Health, Law, Policy & Management; Research Health Scientist, VA Center for Healthcare Organization and Implementation Research

Gemmae M. Fix, PhD is an applied medical anthropologist with training in health services research.  She uses ethnographic methods to examine patient and provider behaviors, including patient self-management and adherence.  She has done work in hypertension, cardiovascular disease and HIV care, including an intervention that used storytelling to improve hypertension self-management. She has also conducted research examining technologies to engage patients in care. More broadly, she has been involved in the US Department of Veteran Health Administration’s patient engagement work both through evaluating patient-centered care programs, as well as developing resources on patient engagement.

Vik Bakhru, MD, MBA Chief Operating Officer, ConsejoSano

Vik Bakhru is a physician and Chief Operating Officer of ConsejoSano, a multicultural health technology platform dedicated to improving quality care for vulnerable and underserved populations. He is the Founder and Chairman of the Board of Directors of the Foundation for international Medicine Relief of Children. Vik holds a B.A. in Economics and a B.S. in Biology from The Columbia College of Arts & Sciences of The George Washington University, and an M.D. from The George Washington University School of Medicine & Health Sciences, and an M.B.A. from The Wharton School of the University of Pennsylvannia.

Sean Glynn, MSOB Director Of Operations for North America, HealthBeacon

Sean Glynn launched the US Operations for award winning digital therapeutics leader,  HealthBeacon two years ago.  The Dublin, Ireland based company’s smart tools for managing injectable medication helps to keep patients on time and on track with treatment while providing critical adherence and persistence data to clinicians and manufacturers.  Sean has worked for global brands such as Fidelity Investments and Accenture, and has consulted to Pharma leaders GlaxoSmithKline and AstraZeneca.  In his role as Director of Operations at HealthBeacon, Sean is responsible for developing the Boston office and introducing HealthBeacon to the US market.

Michael Docktor, MD Pediatric Gastroenterologist, Clinical Director of Innovation and Director of Clinical Mobile Solutions, Boston Children’s Hospital

Michael Docktor is a gastroenterologist at Boston Children’s Hospital and specializes in caring for children with Inflammatory Bowel Disease. He serves as the Clinical Director of Innovation and Director of Clinical Mobile Solutions at the hospital and is passionate about the intersection of technology, design and medicine. Michael believes there is incredible power in thoughtfully designed systems, engaging user experiences and simplicity and strives to help clinicians do their best work in engaging, educating and caring for their patients. Michael is co-founder of Hacking Pediatrics, Dock Health and Health Voyager.

Christina Duczakowski, BA Senior Manager, Pharmacy Growth and Product Development, CVS Health

As a Senior Manager of Pharmacy Growth and Product Development at CVS Health, Christina is responsible for developing and enhancing patient care programs delivered through CVS’s 9,800+ retail pharmacy locations. She leads innovation and implementation of new products, strategies, and solutions aimed at improving medication adherence and health outcomes. Her work helps patients on their path to better health by targeting causes of non-adherence including patient understanding and education, therapy regimen complexity, forgetfulness, side effects, and access to filling.

Prior to joining CVS Health, Christina was at Boston Health Economics, Inc. where she focused on designing and conducting research focused on assessing the value of medical technologies. Christina received her Bachelor of Arts in Health and Societies from the University of Pennsylvania.

The Realities of AI in Healthcare

The advent of new technologies, from those still nascent, such as blockchain, to those more mature, such as health-focused wearables, have firms scrambling to leverage the data they are collecting to create further buy-in to their ecosystems. Among these new technologies, AI has been gaining traction for its potential to inform decision-making without direct human input. Patients provide the data, analytics firms analyze the data, and physicians allow the results to inform their treatment options. Our panelists will discuss how they expect to engage different parties in the face of hot-button topics like patient privacy and the role of physicians moving forward, and the challenges of changing AI technology’s image from a machine that simply crunches data to one that can create novel treatments.

MODERATOR: Venkat Venkatraman, PhD, MBA, B. tech David J. McGrath Jr. Professor in Management, Boston University Questrom School of Business

Professor Venkatraman is the David J. McGrath Jr. Professor in Management with joint appointments in the IS and Strategy & Innovation Departments. He is the author of The Digital Matrix: New Rules for Business Transformation through Technology published in 2017. He is one of the most cited scholars in management according to Google Scholars. His award-winning research has been published in leading academic and practitioner journals. He has consulted and delivered management workshops on digital strategy with leading companies such as IBM, Microsoft, Ericsson, Merck, Federal Express, Canal +, BT and Visa.

Alex Waldron, BA, BA Chief Commercial Officer, Pear Therapeutics

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations.

He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals.

Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

Katherine P. Andriole, PhD Director of Research Strategy and Operations, MGH & BWH Center for Clinical Data Science; Associate Professor of Radiology, Brigham and Women’s Hospital Department of Radiology, Harvard Medical School

Dr. Andriole studied Biomedical and Electrical Engineering and Medicine at Duke and Yale Universities, and did fellowships at UCLA and UCSF Departments of Radiology.  At UCSF, she was instrumental in designing, building and implementing picture archiving and communication systems before they became commercial entities.  Her research has involved technical as well as clinically-relevant developments in medical informatics, image analysis, business analytics, and machine learning.  Dr. Andriole has taught formal courses, directed fellowships in biomedical imaging and informatics, and mentored more than 70 trainees. She has served in multiple leadership roles for the Society of Imaging Informatics in Medicine, currently serves on the Radiological Society of North America (RSNA) Radiology Informatics Committee and the RSNA Machine Learning Steering Committee, and is the Senior Scientist for Education at the American College of Radiology Data Science Institute.  She is an Associate Editor of the Journal of Medical Imaging and Radiology: Artificial Intelligence.

Atul R. Nayak, MBA, MS, BS Director, External Innovation (Delivery, Devices, Connected Systems & Digital Health), Eli Lilly

Atul Nayak, Director of External Innovation at Eli Lilly, focuses on Connected Care and Digital Health initiatives across therapeutic areas. Atul’s remit includes assessing technologies, creating business cases and recommending operating models, besides feeding into Lilly’s long-term strategic plan. He has executed market assessment, forecasting, due diligence & business development assignments in support of Lilly’s vision of improving global health. Specifically, he has played pivotal roles in Lilly’s recent Digital Health deals.

Atul has 13 years of experience in the medical device field. He was most recently part of the Device group at Sanofi, working on external innovation as well as internal development programs.

Atul is passionate about the opportunity new technologies present to transform healthcare. He is particularly interested in the intersection of behavioral science and digital health and its potential to prevent disease, identify novel biomarkers, improve outcomes and reduce healthcare costs.

Kelley Erb, BS, Ph.D Director, Digital Medicine, Early Clinical Development, Pfizer

At Pfizer, Kelley serves as project leader for digital medicine programs aimed at developing, validating, and implementing novel digital endpoints in clinical trials for asset teams across the portfolio.  In that role he has led and managed research collaborations, technology selection, and project execution toward the development of novel endpoints for psychiatric and movement disorders indications.  Kelley has a background in engineering and neuroscience, with experience in both the defense and medical device industries before coming to the pharmaceutical industry.  He holds a B.S. in mechanical engineering and a Ph.D. in Anatomy and Neurobiology.

Defining the Value in Value-Based Care

In theory, Accountable Care Organizations (ACOs) incentivize better coordinated and integrated patient care as a means to both improve outcomes and increase efficiency, while at the same time containing costs. As more healthcare delivery organizations move into ACOs and other risk-based payment models, what effect is this shift having on patient care and outcomes in practice? Are these new structures truly creating a more integrated and beneficial experience for patients while simultaneously delivering their promised cost savings? In discussing the current shift towards value-based care, our panelists will address the barriers to effective implementation, progress towards improved patient care, and topics ranging from the political climate to the Massachusetts Medicaid ACO.

MODERATOR: Diane Shapiro, MHA Chief Operating Officer, Mount Auburn Cambridge Independent Practice Association

Diane Shapiro is a healthcare leader recognized for expertise in combining strategy development, program design and outstanding implementation.  Her background includes overseeing operations in multi-specialty group practices, accountable care organizations, health plans, and management services organizations.   She has advanced the strategy and mission of the organizations through identifying ways to grow services and market share, reduce medical expenses, improve operational efficiency and enhance the experience for patients, clinicians and staff.  She has developed and implemented transformational initiatives in the areas of quality and performance, patient-centered medical homes, and value-based care reimbursement models.

Diane is the COO of the Mount Auburn Cambridge Independent Practice Association (MACIPA) where she oversees the quality improvement, contracting, care management, finance, social work, human resources and pharmacy departments.  Previously, Diane was the COO of Dedham Medical Associates (Atrius Health) where she had responsibility for 25 clinical departments.  She also developed the Quality and Performance, Continuous Improvement, Service Excellence and Patient Advisory Council programs.  Previous experience includes senior roles at Caritas Medical Group/Norwood Hospital, Wellpoint, and Goddard Medical Associates, as well as consulting to various healthcare organizations.

Diane has a BA in Psychology from Tulane University, and a Master of Health Administration from Tulane University School of Public Health.  She studied at the School for International Training in England, and has completed IHI’s Physician Practice Coach Program.

Catherine Harrison, MPA Deputy Director of Policy for Care Delivery Transformation and Strategy, Health Policy Commission

As Deputy Policy Director, Care Delivery Transformation and Strategy, at the Massachusetts Health Policy Commission, Catherine oversees programs and policy initiatives designed to encourage delivery of accountable, patient-centered, high-value care.  These include setting standards for accountable care organizations, defining core competencies for the integration of behavioral health into primary care, and designing investments for medical-community partnerships to address the social determinants of health.  Before joining the HPC, Catherine served in the MA Executive Office of Health and Human Services, where she managed the design and implementation of a demonstration program to integrate Medicaid and Medicare benefits for individuals with dual eligibility.  Catherine began her career in Washington, D.C., as a health policy journalist and later as a manager with the strategic advisory firm Avalere Health.  She earned a B.A in Political Science from Carleton College and holds a Master in Public Affairs from the Woodrow Wilson School at Princeton University.

Marc Spooner, MBA, BA Executive Vice President of Commercial and Government Products, Tufts Health Plan

Marc has oversight of Tufts Health Plan’s three product lines – Commercial Products, Senior Products and Public Plans – and business diversity. He works closely with the division presidents to identify opportunities within and across the business lines to maximize business results and continue Tufts Health Plan’s delivery of nationally recognized insurance offerings.

Marc joined Tufts Health Plan in 2004, and has served as president of the Commercial Products division, which has been consistently ranked among the top quality commercial plans in the country by the National Committee for Quality Assurance (NCQA). Prior that he served as senior vice president of health care services, vice president of provider contracting and vice president of strategy and product development. Prior to joining Tufts Health Plan, Marc worked for Deloitte Consulting, where he focused on the health insurance market.

Luis Miguel Ticona, MD, MPP, MPH Associate Medical Director, Strategy and Implementation, Boston Medical Center

Dr. Ticona is passionate about innovation in primary care, population health, and care for underserved communities. His current work focuses on the development and implementation of population health initiatives for MassHealth ACO patients, including complex care management, and low acuity ED utilization avoidance. He was previously at MGH as a population health fellow, where he led the development and implementation of an intensive home based care alternative to hospitalizations (the MGH Home Hospital program). He completed his residency in internal medicine at the Brigham and Women’s hospital.

Nate Gagne, BA, MBA Chief Financial Officer, New England Quality Care Alliance (NEQCA)

Nate Gagne is Chief Financial Officer for New England Quality Care Alliance (NEQCA), a network of more than 1,700 physicians from across eastern Massachusetts. He has more than 15 years of progressive experience in finance, information technology and data analytics management, spending the past 10 years in the healthcare industry. Before focusing his career in healthcare, Nate led consulting engagements with a diverse set of clients on process re-design and system implementation efforts to increase organizational efficiencies.

Since joining NEQCA in 2012, Nate has successfully improved and streamlined management reporting and population health analytics. He holds multiple committee positions, including serving as Lead Staff for the Finance and Funds Flow Committee and Chairman for the Wellforce Care Plan Finance and Funds Flow Committee. Most recently, Nate was instrumental in the successful launch of the NEQCA Accountable Care Organization and NEQCA’s Next Generation ACO, and now serves as the Chief Financial Officer and Treasurer for both entities.

Nate holds a Bachelor’s degree in Finance from Bentley University and a Master’s in Business Administration from Babson College.

Closing Keynote: Moving To The Third Curve of Health Care

Harold L. Paz, MD, MS Executive Vice President and Chief Medical Officer, Aetna

Harold L. Paz, M.D., M.S., is executive vice president and chief medical officer for Aetna. He leads clinical strategy and policy at the intersection of all of Aetna’s domestic and global businesses. He is responsible for driving clinical innovation to improve member experience, quality and cost in all areas of the health care delivery system.

Before joining Aetna in 2014, Dr. Paz served as chief executive officer of Penn State Hershey Medical Center and Health System, senior vice president for Health Affairs for Penn State University, dean of its College of Medicine and professor of medicine and public health sciences for eight years. Prior to his appointment to Penn State, he spent 11 years as dean of the Robert Wood Johnson Medical School and chief executive officer of Robert Wood Johnson University Medical Group.

Dr. Paz has focused his research and teaching on clinical outcomes, health care effectiveness and personalized health.  Currently, he is professor adjunct of internal medicine at Yale University School of Medicine and remains clinically active in pulmonary medicine at the West Haven Veterans Administration Hospital.

Dr. Paz received his bachelor’s degree from the University of Rochester, a master of science in life science engineering from Tufts University, and his medical degree from the University of Rochester School of Medicine and Dentistry. He completed his residency at Northwestern University, where he served as chief medical resident and instructor in clinical medicine.